ArticleFuture oncology (London, England)2025
A real-world evaluation of the rapid diagnostic clinic roll out in South East London.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRapid Diagnostic Clinics (RDCs) are an established urgent suspected cancer pathway in England and Wales for patients presenting with non-site-specific (NSS) but concerning symptoms for cancer.
methodsThis evaluation included data from a six-month period from 1 September 2022 to 28 February 2023. Information on all patients seen at the three South East London (SEL) RDCs within this six month period was extracted from the REDCap database. Data were analyzed according to several evaluation domains: efficiency, effectiveness (including information on patient demographics, number of referrals, referral outcomes) and patient and GP experience.
resultsEight hundred and sixty-two patients were seen by the SEL RDCs. Most patients came from referrals from general practitioners (GPs) (93%). Only 24 patients (4.5%) were re-referred to the RDC or another specialty within 90 days of discharge and none of these patients were subsequently diagnosed with cancer. There were 47 subsequent cancer diagnoses (6%). The proportion of serious benign conditions diagnosed ranged from 15% to 19% per month. Patient and GP experiences were very positive about the service.
conclusionsThis evaluation has demonstrated that the SEL RDC services provide an effective pathway for the management of patients with concerning non-site-specific symptoms with the ability to diagnose both cancer and non-cancer conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.